GET DAILY SIGNALS4D Molecular Therapeutics (FDMT): What Investors Should Watch in the Q3 2026 Report
Key Takeaways
- 4D Molecular Therapeutics is expected to report third-quarter 2026 results around November 10, 2026, with consensus estimates calling for a net loss near $1.04 per share.
- Revenue is expected to rise sharply year over year, from roughly $90,000 in the prior-year quarter to an estimated low single-digit millions, driven by Otsuka collaboration cost-sharing.
- Investors will focus less on the headline loss and more on clinical milestones for lead gene-therapy candidate 4D-150 in wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
- The pivotal 4FRONT-1 Phase 3 trial in wet AMD completed randomization (523 patients), with topline data expected in the first half of 2027.
- The company's cash position is projected to fund operations into the second half of 2028, reducing near-term dilution risk.
- For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Discover Trending AI Robots to explore AI-driven trading strategies for stocks like FDMT.
Why This Earnings Report Matters
As a clinical-stage biotechnology company, 4D Molecular Therapeutics (FDMT) generates minimal product revenue, so quarterly results are defined less by profitability and more by pipeline execution and balance-sheet runway. The upcoming report matters because it arrives amid pivotal progress for 4D-150, its lead gene-therapy candidate for wet AMD and DME. With the 4FRONT-1 Phase 3 trial fully randomized and 4FRONT-2 enrollment nearing completion, investors are watching for confirmation of timelines and trial progress. Research and development (R&D) spending continues to climb as these late-stage programs advance, making cash guidance a key signal. The report offers a checkpoint on both clinical momentum and financial durability heading into a catalyst-rich 2027. I also checked this using Tickeron’s AI Screener to see how FDMT compares to others in the industry.
Earnings Expectations
Analysts expect 4D Molecular Therapeutics to report a net loss of roughly $1.04 per share for the third quarter of 2026, with revenue consensus estimates clustering in the low single-digit millions (around $3.5 million). That revenue figure reflects continued cost-sharing and reimbursement under the company's Otsuka collaboration rather than product sales, and it would represent a substantial increase from the approximately $90,000 recorded a year earlier.
For context, the company posted a loss of $1.04 per share in the second quarter of 2026, missing the roughly $1.01–$1.02 consensus, while revenue of $3.78 million exceeded estimates. Earnings per share (EPS) surprises have historically driven outsized moves in FDMT shares, though the far larger catalyst for this stock remains clinical data and trial-enrollment updates rather than a beat or miss on the bottom line.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter report is shaped more by the company's clinical narrative than by its financials. FDMT shares have been volatile around recent earnings releases, with modest post-earnings moves in recent quarters as investors weighed pipeline updates against widening operating losses. Heading into this report, attention is centered on any updates regarding 4FRONT-1 topline timing, 4FRONT-2 enrollment completion, and the PRISM and SPECTRA two-year data readouts. Key risk factors include potential delays in trial timelines, higher-than-expected R&D spending, and broader weakness in biotechnology and gene-therapy valuations. A reaffirmation of the cash runway into the second half of 2028 would likely provide reassurance to investors.
Forward Outlook and Key Factors to Monitor
Looking beyond the third-quarter print, the primary drivers for FDMT are clinical rather than financial. The company expects topline data from the 4FRONT-1 Phase 3 trial in wet AMD in the first half of 2027, with 4FRONT-2 topline data anticipated in the second half of 2027. These readouts represent the single most important catalysts for the stock, as they will determine whether 4D-150 can become a commercially viable gene therapy for a large ophthalmology market.
Nearer term, investors should monitor several items. Two-year data from the PRISM Phase 2b trial in wet AMD is expected to be presented at a scientific conference, and two-year SPECTRA data in DME is anticipated in the second half of 2026. The company also plans to initiate a global Phase 3 trial in DME and to share an update on its 4D-710 program for cystic fibrosis lung disease.
On the financial side, watch the trajectory of R&D expenses, which have risen sharply as late-stage trials accelerate. Management's commentary on cash runway, collaboration payments from Otsuka, and any future financing needs will be important for assessing dilution risk. As always with clinical-stage biotech, the balance between execution and capital discipline will be a central theme.
AI Tools in My Research Process
When analyzing clinical-stage names like FDMT, I often rely on Tickeron’s AI Screener to quickly scan for comparable setups across the biotech sector. It allows me to filter by technical patterns, fundamentals, and AI-driven signals in one place, which helps confirm whether current valuations align with peers before earnings season intensifies. The tool has become a regular part of my workflow for staying organized amid multiple catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FDMT in downward trend: 10-day moving average broke below 50-day moving average on October 08, 2026
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
FDMT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FDMT's RSI Indicator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 57 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 76 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement